CY1107433T1 - Παραγωγα 1-(2η-πυραζολ-3-υλο)-3-(4-[1-(βενζοϋλο)-πιπepιδιν-4-υλομεθυλο]-φαινυλο)-ουριας και συναφεις ενωσεις ως αναστολεις της ρ38 κινασης και/ή tnf-αναστολεις για την αντιμετωπιση φλεγμονων - Google Patents
Παραγωγα 1-(2η-πυραζολ-3-υλο)-3-(4-[1-(βενζοϋλο)-πιπepιδιν-4-υλομεθυλο]-φαινυλο)-ουριας και συναφεις ενωσεις ως αναστολεις της ρ38 κινασης και/ή tnf-αναστολεις για την αντιμετωπιση φλεγμονωνInfo
- Publication number
- CY1107433T1 CY1107433T1 CY20071100359T CY071100359T CY1107433T1 CY 1107433 T1 CY1107433 T1 CY 1107433T1 CY 20071100359 T CY20071100359 T CY 20071100359T CY 071100359 T CY071100359 T CY 071100359T CY 1107433 T1 CY1107433 T1 CY 1107433T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- pipepidin
- benzoyloyl
- inflammations
- pyrazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει ενώσεις του τύπου (I) όπου ( ) είναι προαιρετική γέφυρα αιθυλενίου· R1 είναι αλκύλιο, κυκλοαλκύλιο, αρύλιο ή αρύλιο υποκατεστημένο με έναν ή περισσότερους υποκατάστατες επιλεγόμενους από αλκύλιο, αλκοξυ ομάδα και αμινο ομάδα, ή R1 είναι πυριδύλιο ή πυριδύλιο υποκατεστημένο με έναν ή περισσότερους υποκατάστατες επιλεγόμενους από αλκύλιο, αλκοξυ ομάδα και αμινο ομάδα· R2 είναι προαιρετικά υποκατεστημένο αλκύλιο, αλκοξυαλκύλιο, προαιρετικά υποκατεστημένο κυκλοαλκυλαλκύλιο, αρυλαλκύλιο, ή R2 είναι αρυλαλκύλιο υποκατεστημένο με έναν ή περισσότερους υποκαταστάτες επιλεγόμενους από αλκύλιο, αλκοξυ ομάδα· Χ είναι -C(O)-, -C(Ο)-CH2-, -S(Ο)2-, ή NH-C(O)-· και Α είναι προαιρετικά υποκατεστημένο αλκύλιο ή άλλοι υποκατάστατες όπως ορίζονται στην αξίωση 1. Φαρμακευτικές συνθέσεις που περιλαμβάνουν τέτοιες ενώσεις, η παρασκευή αυτών, και η φαρμακευτική χρήση αυτών στην αντιμετώπιση παθολογικών καταστάσεων που μπορούν να ελεγχθούν μέσω της αναστολής της p38-κινάσης και/ή του παράγοντα νέκρωσης όγκων (TNF), όπως άσθματος ή φλεγμονής αρθρώσεων.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46828503P | 2003-05-06 | 2003-05-06 | |
| EP04751319A EP1622610B1 (en) | 2003-05-06 | 2004-05-05 | 1-(2h-pyrazol-3-yl)-3-{4-[1-(benzoyl)-piperidin-4-ylmethyl]-phenyl}-urea derivatives and related compounds as inhibitors of p38 kinase and/or tnf inhibitors for the treatment of inflammations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1107433T1 true CY1107433T1 (el) | 2012-12-19 |
Family
ID=28792177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20071100359T CY1107433T1 (el) | 2003-05-06 | 2007-03-15 | Παραγωγα 1-(2η-πυραζολ-3-υλο)-3-(4-[1-(βενζοϋλο)-πιπepιδιν-4-υλομεθυλο]-φαινυλο)-ουριας και συναφεις ενωσεις ως αναστολεις της ρ38 κινασης και/ή tnf-αναστολεις για την αντιμετωπιση φλεγμονων |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7541368B2 (el) |
| EP (1) | EP1622610B1 (el) |
| JP (1) | JP4714150B2 (el) |
| AT (1) | ATE348610T1 (el) |
| AU (2) | AU2004238241A1 (el) |
| BR (1) | BRPI0409991A (el) |
| CA (1) | CA2524043C (el) |
| CL (1) | CL2004000965A1 (el) |
| CY (1) | CY1107433T1 (el) |
| DE (1) | DE602004003806T2 (el) |
| DK (1) | DK1622610T3 (el) |
| ES (1) | ES2277271T3 (el) |
| GB (1) | GB0320244D0 (el) |
| HN (1) | HN2004000150A (el) |
| HR (1) | HRP20070020T3 (el) |
| JO (1) | JO2473B1 (el) |
| MX (1) | MXPA05011400A (el) |
| MY (1) | MY140830A (el) |
| PA (1) | PA8601901A1 (el) |
| PE (1) | PE20050523A1 (el) |
| PL (1) | PL1622610T3 (el) |
| PT (1) | PT1622610E (el) |
| SI (1) | SI1622610T1 (el) |
| TW (1) | TWI335223B (el) |
| UY (1) | UY28310A1 (el) |
| WO (1) | WO2004100946A1 (el) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| ES2308523T3 (es) * | 2004-06-23 | 2008-12-01 | Eli Lilly And Company | Inhibidores de quinasa. |
| JP4084836B2 (ja) | 2004-08-12 | 2008-04-30 | ファイザー・インク | ｐ３８ＭＡＰキナーゼインヒビターとしてのトリアゾロピリジニルスルファニル誘導体 |
| DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| SG175599A1 (en) | 2006-01-31 | 2011-11-28 | Array Biopharma Inc | Kinase inhibitors and methods of use thereof |
| US20090270350A1 (en) * | 2006-02-10 | 2009-10-29 | Pfizer Inc. | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives |
| WO2007113005A2 (en) * | 2006-04-03 | 2007-10-11 | European Molecular Biology Laboratory (Embl) | 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors |
| US7666888B2 (en) | 2006-07-20 | 2010-02-23 | Amgen Inc. | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 |
| AU2007288245A1 (en) | 2006-08-24 | 2008-02-28 | Novartis Ag | 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyrazol-3-yl) -thiazole derivatives as well as related compounds as stearoyl-CoA desaturase (SCD) inhibitors for the treatment of metabolic, cardiovascular and other disorders |
| CA2662574A1 (en) | 2006-09-22 | 2008-03-27 | Novartis Ag | Heterocyclic organic compounds |
| EA200900820A1 (ru) | 2006-12-20 | 2010-02-26 | Новартис Аг | 2-замещенные 5-членные гетероциклы в качестве ингибиторов стеароил-соа-десатуразы (ссд) |
| DE102007047737A1 (de) * | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
| EA020641B1 (ru) * | 2008-10-02 | 2014-12-30 | Респайверт Лимитед | Производные n-(1-фенил-3-алкилпиразол-5-ил)-n'-арилмочевины |
| GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| EP2370429B1 (en) * | 2008-12-11 | 2016-04-20 | Respivert Limited | P38 map kinase inhibitors |
| EP2236505A1 (de) | 2009-04-03 | 2010-10-06 | Bayer CropScience AG | Acylierte Aminopyridine und - pyridazine als Insektizide |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| WO2011021645A1 (ja) * | 2009-08-19 | 2011-02-24 | 大日本住友製薬株式会社 | ２環性ウレア誘導体、またはその薬学的に許容される塩 |
| US9301929B2 (en) | 2009-11-24 | 2016-04-05 | Merck Sharp & Dohme Corp. | Substituted biaryl derivatives and methods of use thereof |
| US9024041B2 (en) | 2010-04-08 | 2015-05-05 | Respivert Ltd. | P38 MAP kinase inhibitors |
| KR101332830B1 (ko) | 2012-07-05 | 2013-11-27 | 한국화학연구원 | 페닐우레아 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 항암감작제 |
| TWI648282B (zh) * | 2014-03-27 | 2019-01-21 | 印度商托仁特生技有限公司 | 新熔合咪唑苯并噻唑化合物 |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| CA3016161A1 (en) | 2016-03-03 | 2017-09-08 | Cornell University | Small molecule ire1-alpha inhibitors |
| ES2927715T3 (es) | 2017-10-05 | 2022-11-10 | Fulcrum Therapeutics Inc | Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| CA3142097A1 (en) | 2018-05-30 | 2019-12-05 | Washington University | Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof |
| CN113302183A (zh) * | 2018-11-20 | 2021-08-24 | 圣瑞诺有限公司 | 环脲 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001526222A (ja) * | 1997-12-22 | 2001-12-18 | バイエル コーポレイション | アリールおよびヘテロアリール置換複素環尿素を使用するｐ３８キナーゼ活性の阻害 |
| US6316466B1 (en) * | 1998-05-05 | 2001-11-13 | Syntex (U.S.A.) Llc | Pyrazole derivatives P-38 MAP kinase inhibitors |
| UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents |
-
2003
- 2003-08-29 GB GBGB0320244.7A patent/GB0320244D0/en not_active Ceased
-
2004
- 2004-04-25 JO JO200448A patent/JO2473B1/en active
- 2004-05-03 PE PE2004000447A patent/PE20050523A1/es not_active Application Discontinuation
- 2004-05-04 HN HN2004000150A patent/HN2004000150A/es unknown
- 2004-05-05 WO PCT/US2004/013875 patent/WO2004100946A1/en active IP Right Grant
- 2004-05-05 PL PL04751319T patent/PL1622610T3/pl unknown
- 2004-05-05 DE DE602004003806T patent/DE602004003806T2/de not_active Expired - Lifetime
- 2004-05-05 CA CA002524043A patent/CA2524043C/en not_active Expired - Fee Related
- 2004-05-05 ES ES04751319T patent/ES2277271T3/es not_active Expired - Lifetime
- 2004-05-05 JP JP2006532565A patent/JP4714150B2/ja not_active Expired - Fee Related
- 2004-05-05 CL CL200400965A patent/CL2004000965A1/es unknown
- 2004-05-05 BR BRPI0409991-5A patent/BRPI0409991A/pt not_active IP Right Cessation
- 2004-05-05 DK DK04751319T patent/DK1622610T3/da active
- 2004-05-05 EP EP04751319A patent/EP1622610B1/en not_active Expired - Lifetime
- 2004-05-05 MX MXPA05011400A patent/MXPA05011400A/es active IP Right Grant
- 2004-05-05 AU AU2004238241A patent/AU2004238241A1/en not_active Abandoned
- 2004-05-05 PT PT04751319T patent/PT1622610E/pt unknown
- 2004-05-05 AT AT04751319T patent/ATE348610T1/de active
- 2004-05-05 SI SI200430166T patent/SI1622610T1/sl unknown
- 2004-05-06 MY MYPI20041681A patent/MY140830A/en unknown
- 2004-05-06 TW TW093112701A patent/TWI335223B/zh not_active IP Right Cessation
- 2004-05-06 UY UY28310A patent/UY28310A1/es not_active Application Discontinuation
- 2004-05-06 PA PA20048601901A patent/PA8601901A1/es unknown
-
2005
- 2005-11-01 US US11/264,063 patent/US7541368B2/en not_active Expired - Fee Related
-
2007
- 2007-01-19 HR HR20070020T patent/HRP20070020T3/xx unknown
- 2007-03-15 CY CY20071100359T patent/CY1107433T1/el unknown
-
2010
- 2010-10-26 AU AU2010236021A patent/AU2010236021A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004238241A1 (en) | 2004-11-25 |
| TWI335223B (en) | 2011-01-01 |
| US7541368B2 (en) | 2009-06-02 |
| ES2277271T3 (es) | 2007-07-01 |
| US20060063796A1 (en) | 2006-03-23 |
| CA2524043A1 (en) | 2004-11-25 |
| DE602004003806D1 (de) | 2007-02-01 |
| PA8601901A1 (es) | 2004-11-26 |
| UY28310A1 (es) | 2004-11-30 |
| GB0320244D0 (en) | 2003-10-01 |
| MXPA05011400A (es) | 2005-12-12 |
| JO2473B1 (en) | 2009-01-20 |
| PT1622610E (pt) | 2007-02-28 |
| DK1622610T3 (da) | 2007-04-23 |
| PL1622610T3 (pl) | 2007-05-31 |
| CL2004000965A1 (es) | 2005-04-22 |
| JP2007502324A (ja) | 2007-02-08 |
| CA2524043C (en) | 2009-12-29 |
| TW200509912A (en) | 2005-03-16 |
| AU2010236021A1 (en) | 2010-11-18 |
| BRPI0409991A (pt) | 2006-05-09 |
| JP4714150B2 (ja) | 2011-06-29 |
| EP1622610B1 (en) | 2006-12-20 |
| HRP20070020T3 (en) | 2007-04-30 |
| HN2004000150A (es) | 2008-03-03 |
| EP1622610A1 (en) | 2006-02-08 |
| MY140830A (en) | 2010-01-29 |
| DE602004003806T2 (de) | 2007-11-22 |
| PE20050523A1 (es) | 2005-07-07 |
| WO2004100946A1 (en) | 2004-11-25 |
| ATE348610T1 (de) | 2007-01-15 |
| SI1622610T1 (sl) | 2007-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107433T1 (el) | Παραγωγα 1-(2η-πυραζολ-3-υλο)-3-(4-[1-(βενζοϋλο)-πιπepιδιν-4-υλομεθυλο]-φαινυλο)-ουριας και συναφεις ενωσεις ως αναστολεις της ρ38 κινασης και/ή tnf-αναστολεις για την αντιμετωπιση φλεγμονων | |
| CY1114803T1 (el) | Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης | |
| EA200700902A1 (ru) | 3-ариламинопиридиновые производные | |
| SE0402762D0 (sv) | Indazole sulphonamide derivatives | |
| GEP20053600B (en) | 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors | |
| CY1112084T1 (el) | Παραγωγα 5-φαινυλθειαζολης και χρηση ως αναστολεις της κινασης ρi3 | |
| MY141220A (en) | Pyrazole derivatives as inhibitors of receptor tyrosine kinases | |
| ATE371656T1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
| UA88012C2 (uk) | Похідні хіназоліндіону як інгібітори parp | |
| ATE361300T1 (de) | Derivate von heteroarylnitrilverbindungen | |
| IL175716A (en) | 2- (4-Bromo- or 4-Methyl-Phenylamino) -6-Oxo-1,6-Dihydropyridines and their use in drug preparation | |
| DE60333387D1 (de) | Triazolopyridazine als proteinkinase-inhibitoren | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| MX2007009372A (es) | Nuevos compuestos ii derivados de 2-piridina como inhibidores de elastasa neutrofila. | |
| BRPI0508107A (pt) | derivados de indazol e composições farmacêuticas contendo os mesmos | |
| MXPA04003439A (es) | Compuestos de maleimida 3,4 disustituidos como antagonistas de receptor de quimiocina cxc. | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| ATE359791T1 (de) | Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer | |
| DK1641454T3 (da) | Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere | |
| SE0302573D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| SE0300908D0 (sv) | Azaindole derivatives, preparations thereof, uses thereof and compositions containing them | |
| DE60106409D1 (de) | 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen | |
| EA200501233A1 (ru) | 4-аминопиримидин-5-он | |
| SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| ATE390923T1 (de) | Topoisomerase-giftmittel |